Literature DB >> 16674323

Current trends in the use of pharmacoeconomics and outcomes research in europe.

M Drummond1, D Dubois, L Garattini, B Horisberger, B Jönsson, I S Kristiansen, C Le Pen, C G Pinto, P B Poulsen, J Rovira, F Rutten, M G von der Schulenburg, H Sintonen.   

Abstract

Year:  1999        PMID： 16674323     DOI： 10.1046/j.1524-4733.1999.25003.x

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  22 in total

1.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.

Authors:  Hans-Martin Späth; Marie Charavel; Magali Morelle; Marie-Odile Carrere
Journal:  Pharm World Sci       Date:  2003-12

5.  The incorporation of potential confounding variables in Markov models.

Authors:  Mark J C Nuijten; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.

Authors:  Mark J C Nuijten; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Authors:  Naoki Ikegami; Michael Drummond; Shunichi Fukuhara; Shuzo Nishimura; George W Torrance; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 8.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model.

Authors:  Mark J C Nuijten; Joszef Kosa
Journal:  Eur J Health Econ       Date:  2004-06

10.  Argentine valuation of the EQ-5D health states.

Authors:  Federico Ariel Augustovski; Vilma Edit Irazola; Alberto Pascual Velazquez; Luz Gibbons; Benjamin M Craig
Journal:  Value Health       Date:  2008-11-12       Impact factor: 5.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.